" class="no-js "lang="en-US"> OstomyCure Announces Milestone in Pivotal TIES Clinical Trial
Monday, April 15, 2024

OstomyCure Announces Completion of Patient Recruitment Milestone in Pivotal TIES Clinical Trial

OstomyCure, a clinical-stage medtech company developing revolutionary technologies to transform the lives of people with a stoma, today announced that it has successfully completed a crucial patient recruitment milestone in its pivotal clinical trial of the company’s proprietary TIES implant technology.

TIES is an innovative titanium port, which is implanted within a stoma and used to attach a lid to effectively open and close the stoma at the user’s convenience. The device is designed to end the reliance on a permanent ostomy bag for people with an ileostomy, enabling patients to take back control of their lives. 20 patients have now been implanted with the device with participating hospitals in the UK, Sweden, Poland, Austria, and India. The patients will be monitored for a further six months to fully assess safety and performance of the technology. The analysis of the clinical data from these patients will be included in the regulatory submissions for a CE Mark under the EU Medical Device Regulation (MDR). Patients will continue to be recruited during the regulatory process to further build clinical evidence for the device.

Professor Manish Chand, Consultant Colorectal & Robotic Surgeon, University College Hospital, London said, “Implanting the TIES® device has been very straightforward. There has been very little innovation in stoma therapy for many years, so I’m really looking forward to seeing my patients enjoy the benefits of TIES® as they learn to live with this exciting new technology.”

OstomyCure, CEO, Dr Johan Jarte, added, “Completing this milestone for our pivotal clinical trial is a crucial step in bringing this novel device closer to regulatory clearance and introducing it to a large patient population urgently in need of solutions to improve their quality of life. We will quickly compile the data ready for our EU regulatory submissions. We are incredibly grateful for the commitment and enthusiasm of patients and clinicians who have taken part in the trial.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more